Faculty’s most recent publications:

Sikander Ailawadhi

1. Ailawadhi S, Sung KW, Carlson LA, Baer, MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Therapeutics 2007; 32: 1-4.
2. Ailawadhi S, Nagase H, Khoury T, Yu J, Tan D, Black J, Brattain M, Javle M. Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepato-Gastroenterol 2007; 54:1339-1344.
3. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM. Malignant gastroparesis: pathogenesis and management of an under-recognized disorder. J Support Oncol 2007; 5(8): 355-363.
4. Ailawadhi S, Derby L, Natarajan R, Reid M, Ramnath N. Erlotinib for metastatic non-small-cell lung cancer: First-, second- or third-line setting – does it matter? Oncology 2009; 76(2): 85-90.
5. Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma. 2009; 50(7): 1096-1101.

Dan Douer

1. Basile LA, Gallaher TK, Shibata D, Miller JD, Douer D: Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J Transl Med 6:26, 2008.
2. Douer D: Is Asparaginase A Critical Component in the Treatment Acute Lymphoblastic Leukemia? Best Practice & Research Clinical Hematology 21:647–658, 2008.
3. Choi SH, Worswick S, ByunH-M, Shear T, Soussa JC, Wolff , Douer D, Guillermo Garcia-Manero, Liang G, Yang AS. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. International J Cancer. In press 2009

Allen Yang

1. Dowd CL, Sutch BT, Haworth IS, Eritja R, Marquez VE, Yang AS: Incorporation of zebularine from its 2'-deoxyribonucleoside triphosphate derivative and activity as a template-coding nucleobase. Nucleosides Nucleotides Nucleic Acids 27(2):131-45, 2008.
2. Heo K, Kim H, Choi SH, Choi J, Kim K, Gu J, Lieber MR, Yang AS, An W: FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16. Mol Cell 30(1):86-97, 2008.
3. Byun HM, Choi SH, Laird PW, Trinh B, Siddiqui MA, Marquez VE, Yang AS: 2'-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: A novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett 266(2):238-48, 2008.

Howard Liebman

1. Kuter D, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Sunkara UK, Liebman HA, Murali MS, Slovick FT, Vellenga E, Arepally GM, Bourgeois E, Guthrie, Jr TH, Newland A, Wasser JS, Firstenberg BA, Hamburg SI, Lahuerta-Palacios JJ, Lefrère F, Lichtin AE, Macik BG, Tarantino MD, Terebelo HR, Viallard J-F, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol J: Randomized, controlled, 6-month evaluation of AMG-531 in patients with chronic immune thrombocytopenic purpura. Lancet 371:395-403, 2008.
2. Liebman HA: Heparin-induced thrombocytopenia: Diagnosis and Management. Vascular 16 (suppl 1) 91-96, 2008.
3. Alexy T, Tucker S, Boyle S, Rowe VL, Weaver FA, Liebman HA: Heparin-PF4 antibodies are frequent following vascular surgery, but are not a frequent cause of graft thrombosis or thrombocytopenia. Journal of Vascular Surgery 48: 377-381, 2008.
4. Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA: Subclinical hemostatic activation and surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU International 2008; 102:1086-1091.
5. O’Connell C, Liebman HA: Novel anticoagulants in the management of cancer-associated venous thromboembolism. Expert Review of Hematology 2008; 1:175-182.
6. Liebman HA: Viral-Associated chronic immune thrombocytopenia, Hematology 2008; 2008:212-218.
7. Liebman HA: Immune Thrombocytopenia (ITP): An Historical Perspective. Hematology. 2008; 2008: 205.
8. Cheung E, Liebman HA: Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics: Targets & Therapy 2009; 3: 1-6.
9. Cines DB, Liebman HA, Stasi R: Pathobiology of secondary immune thrombocytopenia. Seminars in Hematology 2009; 46: S2-S14.
10. Liebman HA: Recognizing and treating secondary ITP associated with
    lymphoproliferative disorders. Seminars in Hematology 2009; 46:S33-S3611. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP Syndrome: A diverse set of disorders with different immune mechanisms. Blood 2009-published on line 4/24/2009

Ilene Weitz

1. Weitz IC, Liebman HA: The role of oral anticoagulants in tumor biology. Semin Thromb Hemost 33(7):695-698, 2007.
2. Oliveira B, Arkfeld DG, Weitz IC, Shinada S, Ehersmann G: Successful rituximab therapy of an acquired factor VIII inhibitor in a patient with rheumatoid arthritis. J Clin Rheumatol 13:89-91, 2007.
3. Weitz IC, Liebman HA. Oral Anticoagulants and Cancer Survival. Seminars in Thrombosis and Hemostasis 33: 695-698, 2007

Ann Mohrbacher

1. Pullarkat V, Veliz L, Chang K, Mohrbacher A, Teotico AL, Forman SJ, Slovak ML. Therapy-related, mixed-lineage leukemia translocation-positive, monoblastic myeloid sarcoma of the uterus. J Clin Pathol 5: 562-4, 2007.

Casey O’Connell

1. O’Connell C and Liebman H. Novel anticoagulants in the management of cancer-related thrombosis. InPress, Expert Reviews of Hematology.
2. Dolev JC, Maurer T, Springer G, Glesby MJ, Minkoff H, O’Connell C, Young M, Schowalter K, Cox C, Hessol N. Incidence and risk factors for verrucae in women. AIDS 2008; 22:1213-19.

Anil Tulpule

1. Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM: A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Leukemia and Lymphoma 2:374-380, 2007.
2. Robinson KS, Williams ME, vander Jagt RH, Chen P, Herst JA, Tulpule A, et al. Phase II multicenter study of Bendamustin plus Rituximab in patients with relapsed indolent B-cell and Mantle Cell non-Hodgkin’s Lymphoma. J of Clin Oncology. 26 (27): 4473-4479, 2008.

Parkash Gill

1. Cozen W, Gill PS, Salam MT, Nieters A, Masood R, Cockburn MG, Gauderman WJ, Martínez-Maza O, Nathwani BN, Pike MC, Vandenberg D, Hamilton AS, Deapen DK, Mack TM. Interleukin-2, interleukin-12, and interferon-? levels and risk of young adult Hodgkin lymphona: Bloo. 2008 Apr 1;111(7):3377-82
2. Trindade A, Ram Kumar S, Scehnet JS. Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill PS (corresponding), Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos . Blood 2008 Sep 1;112(5):1720-9.
3. Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R. Arch . The sifnificance of EphB4 and EphrinB2 expression and survival in head and neck squamoas cell carcinoma. Otolaryngol Head Neck Surg. 2008 Sep;134(9):985-91.
4. Benedito R, Trindade A, Hirashima M, Henrique D, Lopes-da-Costa L, Rossant J, Gill PS, Duarte A. Loss of Notch signaling induced by Delta-like 4 (DII4) causes arterial caibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol. 2008 Dec 16;8(1):117.
5. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR, Gill PS. The Role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of Ephrin B2 blockade. Blood 2009 Jan 1;113(1):254-63.
6. Kumar R, Ley E, Scehnet JS, Krasnoperov V, Beart R, Gill PS. Reciprocal expression of EphB4 and EphB2 in colon cancer and normal colon, prognostic and therapeutic targeting. Revision Submitted.
7. Krasnoperov V, Kumar R, Scehnet JS, Zozulya S, Reddy S, Ley E, Gill PS. EphB4 monoclonal antibodies targeting multiple epithelial cancers and angiogenesis. Submitted.

Cage Johnson

1. Dang NC, Johnson C, Eslami-Farsani M, Haywood LJ. Myocardial injury or infraction associated with fat embolism in sickle cell diease: A report of three cases with survival. American Journal of Hematology 80(2):133-136, 2008.
2. Adams-Graves P, Lamar K, Johnson C, Corley P. Development and validation of SUMS: An instrument for measuring quality of life of adults with sickle cell disease. American Journal of Hematology 83(7): 558-562, 2008.